Glucocorticoids induce osteoporosis mediated by glucocorticoid receptor-dependent and -independent pathways
Clinically, glucocorticoids (GCs) are widely used to treat inflammation-related diseases; however, their long-term use causes side effects, such as osteoporosis and predisposition to bone fractures, known as glucocorticoid-induced osteoporosis (GIOP). Nr3c1 is the major glucocorticoid receptor, and...
Main Authors: | Yu Jiang, Yajun Lu, Xu Jiang, Jiawei Hu, Rong Li, Yun Liu, Guoxing Zhu, Xiaoxu Rong |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-05-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332220301694 |
Similar Items
-
Glucocorticoid-induced osteoporosis: 2013 update
by: M. Mazzantini, et al.
Published: (2014-07-01) -
The molecular etiology and treatment of glucocorticoid-induced osteoporosis
by: Cheng-Huan Peng, et al.
Published: (2021-01-01) -
REVIEW OF AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CLINICAL GUIDELINES FOR THE PREVENTION AND TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS
by: N. V. Toroptsova
Published: (2018-05-01) -
Regulation of sclerostin in glucocorticoid-induced osteoporosis (GIO) in mice and humans
by: Sylvia Thiele, et al.
Published: (2019-07-01) -
Osteoporosis secundaria y Osteoporosis inducida por glucocorticoides (OIG)
by: Elías Forero Illera
Published: (2006-01-01)